secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001171843-25-004118
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose signs up to $8.5M uncommitted loan from Hanmi for Tuspetinib AML clinical development
--------------------------------------------------------------------------------

- Loan agreement with Hanmi Pharmaceutical for up to $8.5M uncommitted non-revolving facility.
- Funds to be used for Tuspetinib triple drug therapy for newly diagnosed AML, accounts payable, and TUS-related corporate purposes.
- Advances up to $2.5M each, available until Dec 31, 2025; maturity date Aug 31, 2028.
- Loan bears 6% interest per annum; secured by first ranking security on all personal property of Aptose and subsidiary guarantees.
- Previous 2024 facility agreement also exists; new loan is separate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325004118/0001171843-25-004118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325004118/f8k_062625.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer